Boston Scientific has completed the acquisition of US-based firm NxThera and associated Rezūm system to treat benign prostatic hyperplasia (BPH) for a total of $406m.
Originally signed in March, the definitive agreement involved $306m in upfront payments and an additional $100m in potential commercial milestone-based amounts over a four-year period.
Following the closing of the transaction, NxThera is set to be integrated into the Boston Scientific Urology and Pelvic Health business.
The business specialises in treatment needs for men’s and women’s urological and gynaecological disorders. The addition of Rezūm device is expected to complement its symptomatic BPH therapy portfolio that includes GreenLight XPS Laser Therapy system and holmium laser platforms.
Boston Scientific MedSurg executive vice-president and president Dave Pierce said: “We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side-effects of medications.
“The minimally invasive therapy segment is the fastest growing category in the treatment of BPH and, as an office-based procedure, the Rezūm system is appealing to patients, clinicians and payers.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The Rezūm device uses water vapour to eliminate excess prostate tissue and relieve obstruction to flow, resulting in reduced BPH-related symptoms.
Data from a three-year study demonstrated improved clinical progression rates with Rezūm when compared with patients who received daily, long-term medications.
In a separate clinical trial, the system was found to have led to a 51% decrease in BPH symptoms at 24 months after treatment, with a 50% reduction maintained at three years.